UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000044936
Receipt number R000051319
Scientific Title A study to evaluate the effects of functional food on body fat mass -Randomized, placebo-controlled, double-blind, parallel group comparison study-
Date of disclosure of the study information 2021/07/21
Last modified on 2021/07/21 16:23:17

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study to evaluate the effects of functional food on body fat mass -Randomized, placebo-controlled, double-blind, parallel group comparison study-

Acronym

A study to evaluate the effects of functional food on body fat mass

Scientific Title

A study to evaluate the effects of functional food on body fat mass -Randomized, placebo-controlled, double-blind, parallel group comparison study-

Scientific Title:Acronym

A study to evaluate the effects of functional food on body fat mass

Region

Japan


Condition

Condition

None

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate safety and efficacy of intake of the test food for 12 weeks on body fat mass in in healthy adults classified as pre-obese or obese class I

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Abdominal visceral fat area

Key secondary outcomes

Body weight, BMI, body fat percentage, abdominal total fat area, abdominal subcutaneous fat area, body composition (In Body), circumference, questionnaire survey


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Intake 5 tablets of the test food for 12 weeks

Interventions/Control_2

Intake 5 tablets of the placebo food for 12 weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

1) Males and females aged of 20-64 years at the date of informed consent
2) Subjects whose BMI 24 kg/m2 or more and less than 30 kg/m2
3) Subjects who have received a sufficient explanation of the purpose and content of the study, have the consent ability and good understandings, and have agreed voluntarily in writing to participate in the study

Key exclusion criteria

1)Subjects who use pharmaceuticals affecting the study
2)Subjects who have a history of severe kidney disease, heart disease, respiratory disease, endocrine disease, diabetes, etc., and undergoing treatment for them (excluding transient treatment such as colds)
3)Subjects who cannot stop taking supplements and health foods (including foods for specified health use and foods with functional claims) that may affect something for the test in the study period
4)Subjects who declare some allergies to the components of the test food
5)Subjects who have a history of drug/alcohol dependence or a current medical history
6)Subjects who have metal by surgery and others in measurement areas for CT scan
7)Subjects with implantable medical devices such as cardiac pacemakers and implantable cardioverter-defibrillators
8)Claustrophobic
9)Subjects who are currently pregnant or lactating, or who plan to become pregnant in the study period
10)Subjects who are currently participating in other clinical studies that take or apply other foods, pharmaceuticals, cosmetics, or chemicals, who have participated in other clinical studies within the past month from the date of consent, or who plan to participate in others
11)Subjects judged as unsuitable for this study by the principal investigator

Target sample size

80


Research contact person

Name of lead principal investigator

1st name Toru
Middle name
Last name Sagami

Organization

Shinagawa Season Terrace Health Care Clinic

Division name

Doctor

Zip code

108-0075

Address

1-2-70, Konan, Minato-ku, Tokyo The 5th floor of Shinagawa season terrace

TEL

03-3452-3382

Email

shibaura@sempos.or.jp


Public contact

Name of contact person

1st name Eiji
Middle name
Last name Yoshikawa

Organization

KSO Corporation

Division name

Sales department

Zip code

108-0023

Address

1-9-7, Shibaura, Minato-ku, Tokyo The 7th floor of Shibaura omodaka building

TEL

03-3452-7733

Homepage URL


Email

yoshikawa@kso.co.jp


Sponsor or person

Institute

KSO Corporation

Institute

Department

Personal name



Funding Source

Organization

NatureLab.Co.,Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethical Committee of Kobuna Orthopedics Clinic

Address

311-2, Gokammachi, Maebashi Shi, Gumma Ken, 371-0813, Japan

Tel

027-212-5608

Email

sagawa@mc-connect.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

一般財団法人船員保険会 品川シーズンテラス健診クリニック(東京都)


Other administrative information

Date of disclosure of the study information

2021 Year 07 Month 21 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2021 Year 05 Month 11 Day

Date of IRB

2021 Year 05 Month 13 Day

Anticipated trial start date

2021 Year 07 Month 10 Day

Last follow-up date

2021 Year 12 Month 12 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 07 Month 21 Day

Last modified on

2021 Year 07 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051319


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name